share_log

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week Alone

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week Alone

Kiniksa Pharmicals(納斯達克股票代碼:KNSA)在1年內爲股東帶來了可觀的66%的回報率,僅在上週就激增了4.7%
Simply Wall St ·  02/28 07:47

The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you could make more than that. For example, the Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) share price is up 66% in the last 1 year, clearly besting the market return of around 26% (not including dividends). If it can keep that out-performance up over the long term, investors will do very well! Unfortunately the longer term returns are not so good, with the stock falling 4.0% in the last three years.

投資股票的最簡單方法是購買交易所交易基金。但是,如果你選擇正確的個股,你的收入可能不止於此。例如,基尼克薩製藥有限公司(納斯達克股票代碼:KNSA)的股價在過去1年中上漲了66%,顯然超過了約26%(不包括股息)的市場回報率。如果它能長期保持跑贏大盤的表現,那麼投資者就會做得很好!不幸的是,長期回報並不那麼好,該股在過去三年中下跌了4.0%。

Since the stock has added US$65m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.

由於僅在過去一週中,該股的市值就增加了6500萬美元,因此讓我們看看基礎表現是否推動了長期回報。

Kiniksa Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Kiniksa Pharmicals目前尚未盈利,因此大多數分析師會着眼於收入增長,以了解基礎業務的增長速度。當一家公司沒有盈利時,我們通常預計收入會有良好的增長。那是因爲如果收入增長可以忽略不計,而且從來沒有盈利,就很難確信一家公司能否實現可持續發展。

In the last year Kiniksa Pharmaceuticals saw its revenue grow by 41%. We respect that sort of growth, no doubt. Buyers pushed the share price 66% in response, which isn't unreasonable. If revenue stays on trend, there may be plenty more share price gains to come. But before deciding this growth stock is underappreciated, you might want to check out profitability trends (and cash flow)

去年,Kiniksa製藥的收入增長了41%。毫無疑問,我們尊重這種增長。作爲回應,買家將股價推高了66%,這並非不合理。如果收入保持趨勢,股價可能會有更多的上漲。但是,在決定這種成長型股票被低估之前,你可能需要查看盈利趨勢(和現金流)

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

公司的收入和收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。

earnings-and-revenue-growth
NasdaqGS:KNSA Earnings and Revenue Growth February 28th 2024
納斯達克GS:KNSA收益和收入增長 2024年2月28日

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

資產負債表的強度至關重要。可能值得一看我們關於其財務狀況如何隨着時間的推移而變化的免費報告。

A Different Perspective

不同的視角

It's good to see that Kiniksa Pharmaceuticals has rewarded shareholders with a total shareholder return of 66% in the last twelve months. That's better than the annualised return of 4% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. You might want to assess this data-rich visualization of its earnings, revenue and cash flow.

很高興看到Kiniksa Pharmicals在過去十二個月中向股東提供了66%的總股東回報率。這比五年來4%的年化回報率要好,這意味着該公司最近的表現更好。持樂觀態度的人可能會將最近股東總回報率的改善視爲業務本身隨着時間的推移而變得更好。您可能需要評估其收益、收入和現金流的這種數據豐富的可視化效果。

Of course Kiniksa Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,Kiniksa Pharmicalsa可能不是最好的買入股票。因此,您可能希望看到這批免費的成長股。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論